New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

The company's HAMMR device is designed to produce therapeutic proteins inside the human body around the clock. Photo courtesy Rice University

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

From Your Site Articles
Houston Methodist has recruited Dr. Daniela Matei, an expert in ovarian and endometrial cancer, to lead the Dr. Mary and Ron Neal Cancer Center. Photo courtesy Houston Methodist.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.
Fram2, operated by SpaceX, is targeting to launch Monday, March 31. The crew will conduct six TRISH experiments on board. Photo courtesy TRISH.

Houston space org to launch experiments aboard first mission into polar orbit

all aboard

Houston's Translational Research Institute for Space Health, or TRISH, will send its latest experiments into space aboard the Fram2 mission, the first all-civilian human spaceflight mission to launch over the Earth’s polar regions.

Fram2, operated by SpaceX, is targeting to launch Monday, March 31, at NASA’s Kennedy Space Center in Florida. The crew of four is expected to spend several days in polar orbit aboard the SpaceX Dragon spacecraft in low Earth orbit. TRISH’s research projects are among 22 experiments that the crew will conduct onboard.

The crew's findings will add to TRISH's Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program and will be used to help enhance human health and performance during spaceflight missions, including missions to the moon and Mars, according to a release from TRISH.

“The valuable space health data that will be captured during Fram2 will advance our understanding of how humans respond and adapt to the stressors of space,” Jimmy Wu, TRISH deputy director and chief engineer and assistant professor in Baylor’s Center for Space Medicine, said in the release. “Thanks to the continued interest in furthering space health by commercial space crews, each human health research project sent into orbit brings us closer to improving crew member well-being aboard future spaceflight missions.”

The six TRISH projects on Fram2 include:

  • Cognitive and Physiologic Responses in Commercial Space Crew on Short-Duration Missions, led by Dr. Mathias Basner at the University of Pennsylvania Perelman School of Medicine. The crew will wear a Garmin smartwatch and a BioIntelliSense BioButton® medical grade device to track cognitive performance, including memory, spatial orientation, and attention before, during, and after the mission.
  • Otolith and Posture Evaluation II, led by Mark Shelhamer at Johns Hopkins University. The experiment will look at how astronauts’ eyes sense and respond to motion before and after spaceflight to better understand motion sickness in space.
  • REM and CAD Radiation Monitoring for Private Astronaut Spaceflight, led by Stuart George at NASA Johnson Space Center. This experiment will test space radiation exposure over the Earth’s north and south poles and how this impacts crew members.
  • Space Omics + BioBank, led by Richard Gibbs and Harsha Doddapaneni at Baylor College of Medicine. The experiment will use Baylor’s Human Genome Sequencing Center's Genomic Evaluation of Space Travel and Research program to gain insights from pre-flight and post-flight samples from astronauts.
  • Standardized research questionnaires, led by TRISH. The test asks a set of standardized research questionnaires for the crew to collect data on their sleep, personality, health history, team dynamics and immune-related symptoms.
  • Sensorimotor adaptation, led by TRISH. The project collects data before and after flight to understand sensorimotor abilities, change and recovery time to inform future missions to the moon.

TRISH, which is part of BCM’s Center for Space Medicine with partners Caltech and MIT, has launched experiments on numerous space missions to date, including Blue Origin's New Shepard rocket last November and Axiom Space's Ax-3 mission to the International Space Station last January.

The work is "poised to revolutionize our understanding of fundamental physics," according to Rice University. Photo courtesy of Rice University

Houston physicist scores $15.5M grant for high-energy nuclear physics research

FUTURE OF PHYSICS

A team of Rice University physicists has been awarded a prestigious grant from the Department of Energy's Office of Nuclear Physics for their work in high-energy nuclear physics and research into a new state of matter.

The five-year $15.5 million grant will go towards Rice physics and astronomy professor Wei Li's discoveries focused on the Compact Muon Solenoid (CMS), a large, general-purpose particle physics detector built on the Large Hadron Collider (LHC) at CERN, a European organization for nuclear research in France and Switzerland. The work is "poised to revolutionize our understanding of fundamental physics," according to a statement from Rice.

Li's team will work to develop an ultra-fast silicon timing detector, known as the endcap timing layer (ETL), that will provide upgrades to the CMS detector. The ETl is expected to have a time resolution of 30 picoseconds per particle, which will allow for more precise time-of-flight particle identification.

The Rice team is collaborating with others from MIT, Oak Ridge National Lab, the University of Illinois Chicago and University of Kansas. Photo via Rice.edu

This will also help boost the performance of the High-Luminosity Large Hadron Collider (HL-LHC), which is scheduled to launch at CERN in 2029, allowing it to operate at about 10 times the luminosity than originally planned. The ETL also has applications for other colliders apart from the LHC, including the DOE’s electron-ion collider at the Brookhaven National Laboratory in Long Island, New York.

“The ETL will enable breakthrough science in the area of heavy ion collisions, allowing us to delve into the properties of a remarkable new state of matter called the quark-gluon plasma,” Li explained in a statement. “This, in turn, offers invaluable insights into the strong nuclear force that binds particles at the core of matter.”

The ETL is also expected to aid in other areas of physics, including the search for the Higgs particle and understanding the makeup of dark matter.

Li is joined on this work by co-principal investigator Frank Geurts and researchers Nicole Lewis and Mike Matveev from Rice. The team is collaborating with others from MIT, Oak Ridge National Lab, the University of Illinois Chicago and University of Kansas.

Last year, fellow Rice physicist Qimiao Si, a theoretical quantum physicist, earned the prestigious Vannevar Bush Faculty Fellowship grant. The five-year fellowship, with up to $3 million in funding, will go towards his work to establish an unconventional approach to create and control topological states of matter, which plays an important role in materials research and quantum computing.

Meanwhile, the DOE recently tapped three Houston universities to compete in its annual startup competition focused on "high-potential energy technologies,” including one team from Rice.

------

This article originally ran on EnergyCapital.

An annual ranking recognized Rice University again — but the Houston school ranked a tad lower this year. Photo courtesy of Rice

Report: Rice University again ranks among the top schools in nation

hooting in Houston

Rice University has earned yet another accolade worth hooting about.

Niche, an education review and ranking website, has named Rice the ninth best college in the U.S., down from No. 6 last year. The Houston university receives an A+ in nine of the 12 ranking categories, including academics, diversity, and value. It gets an A for the party scene, a B+ for athletics, and a B for safety.

“We’re proud that Niche once again rates Rice not only one of the nation’s top universities, but also one of the nation’s best college values,” university President Reginald DesRoches said in 2022. “This is especially gratifying because Niche reflects the opinions of students and parents who know firsthand what outstanding education opportunities Rice continues to offer.”

Rice regularly ranks highly on lists of the best colleges and universities in the country, including those published by Niche, Forbes, and U.S. News & World Report.

“Rice is an awesome place. I went to Rice because I wanted professors who actually wanted to see their students succeed, and I can confidently say that’s what I found at Rice,” a student wrote in a Niche review. “The classes are thorough but the tests are very reasonable and focus on the material we learned in class.”

Topping Niche’s national list is Yale University, followed by Stanford University, the Massachusetts Institute of Technology, Harvard University, Princeton University, Columbia University, the University of Pennsylvania, and Dartmouth College.

Rice comes in at No. 12 on Niche’s list of the “best value colleges” in the U.S. and ranks first among the best colleges in Texas. Here are the top 10 Texas schools, including the eighth-ranked University of Houston:

1. Rice University
2. University of Texas at Austin
3. Texas A&M University (College Station)
4. Trinity University (San Antonio)
5. Southern Methodist University (University Park)
6. Texas Christian University (Fort Worth)
7. Texas Tech University (Lubbock)
8. University of Houston
9. University of Texas Permian Basin (Odessa)
10. Baylor University (Waco)

Other Houston-area schools in the Texas ranking are:

  • University of Houston – Clear Lake (No. 13)
  • University of St. Thomas (No. 26)
  • University of Houston – Downtown (No. 39)
  • Prairie View A&M University (No. 43)

“Choosing where to go to college is easily one of the most significant — and expensive — decisions of a person’s life. Niche’s mission is to ensure that every college-bound student has access to easy, transparent and free resources … to help them find their best fit,” Luke Skurman, founder and CEO of Niche, says in a news release.

When it comes to promoting social causes, corporations have to find a way to appear genuine over posturing. Photo via Getty Images

Navigating corporate challenge of genuinely supporting social causes, per Rice research

Houston Voices

It is becoming more and more common for companies to promote social causes such as human rights, LGBTQ+ rights, racial justice, and environmental sustainability. But organizations face a tricky dilemma when expressing commitments to helping address social issues: Stakeholders may interpret their words and deeds as shallow rhetoric or insincere posturing.

Terms like “greenwashing” (regarding environmentalism) or “pinkwashing” (regarding LGBTQ+ rights) are on the rise, and they signal heightened suspicions around companies doing something with ostensible objectives of bringing in positive social change.

It's critical for researchers and business leaders to investigate this duality of audience perception: actual virtue versus virtue-signaling. In an age of social media and polarization, consumers are increasingly likely to wonder: Does this company have ulterior motives? Are they trying to cover for their own wrongdoing? Are they actually walking the walk, or are they merely talking the talk?

When can companies avoid such suspicion of being pro-social imposters?

Minjae Kim of Rice Business and Ezra W. Zuckerman Sivan of MIT Sloan School of Management have taken a close look at the conditions under which upholding social norms will make firms appear to be “model citizens” and when it will make them seem like imposters.

Their theory is two-fold: First, those who follow through and do social good in response to an explicit “social mandate” are viewed as “model citizens.” Second, those who go out of their way to do social good without any prompts or social mandates are less likely to be trusted and will be widely viewed as imposters.

Think about the following situation. A “social mandate” is given to a politician when they are asked in an interview what they think about a particular cause. In that context, if they express support, audiences are less likely to suspect the politician of having ulterior motives or pandering to constituents. After all, if the politician does not express support in that situation, that is tantamount to expressing disapproval. Here, the interview question (i.e., “social mandate”) provides a cover of plausible deniability to any suspicions of ulterior motives. Law enforcement (e.g., police, prosecutors) often have this social mandate built into their professions.

But if the politician takes initiative — unprompted — to support the same cause, they will more likely be viewed with suspicion. They may instead appear to seek out social rewards associated with supporting the cause (e.g., good reputation), without the cover of plausible deniability.

To test their theory, Kim and Zuckerman launched a series of experiments involving 509 online participants based in the United States. The experiments sought to determine how respondents perceive individuals who encourage others to abide by social norms. Participants were specifically asked to identify which of two individuals they think are “model citizens” committed to the norm, or “imposters” who are uncommitted but trying to hide their own deviance.

The researchers found that people who encourage others to abide by social norms when prompted (“social mandate”) are perceived as “model citizens,” while those who do the same but without such prompts are more likely to appear as “imposters.” This duality provides a clear guideline for managers engaging in corporate social responsibility: When suspicions are rampant, launching pro-social campaigns without a plausible mandate may heighten suspicion regarding motives.

The larger question is how to build firms and societies where people can safely support norms (that we all support) without being suspected as imposters. After all, we want our own norms and moral principles to govern our lives. But in some situations, we may mistakenly vilify those who are trying to do good, based on the absence of some contextual “social mandate.”

------

This article originally ran on Rice Business Wisdom and was based on research from Minjae Kim, assistant professor of organizational behavior at Rice University Jones Graduate School of Business, and Ezra Zuckerman Sivan, the Alvin J. Siteman (1948) Professor of Strategy and Entrepreneurship at MIT Sloan School of Management.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice, Houston Methodist award $90K for cancer research projects

seed grants

Rice University’s Synthesis X Center, in partnership with the Houston Methodist Neal Cancer Center, announced earlier this month the organizations would award $90,000 in seed grant funding to two projects that could help fight cancer. One would ease the pain of chemotherapy, while the other could change the way the progression of leukemia is tracked.

“We’re excited to be collaborating with the Neal Cancer Center to support collaborative, novel and interdisciplinary proposals to improve cancer care and outcomes,” Han Xiao, Rice professor of chemistry and the director of the SynthX Center, said in a news release. “Together, we can achieve translational excellence.”

The projects

Chemotherapy is one of the most effective cancer treatments, but it can be hard on the body. The human body doesn’t like being injected with radioactive material, especially the skin around the injection point, which can become extremely irritated. For patients in long-term treatment, the skin irritation can be more than just a bother; it can lead to infections that are dangerous to a compromised immune system.

Angel A Marti, a professor of chemistry at Rice University, and Biana Godin, an associate professor of nanoscience at Houston Methodist Research Institute, are experimenting with metal nanoclusters as a way to block radiation at the injection site. The nanocluster could be applied in a cream or a gel on the skin, serving as a type of shield against the harsh radioactive material.

Meanwhile, Yuan Ma, an assistant professor of chemistry at Rice, and Shu-Hsia Chen, a professor of immunology at Houston Methodist Research Institute, are working with m6A. Discovered in the 1970s, m6A is the most prevalent chemical modifier found in mRNA in mammals. It is prevalent in many cancers, including leukemia.

Ma and Chen are working on measuring the amount of m6A in leukemia to see if it can determine the most effective cancer treatments. The team is also experimenting with ways to shut off m6A to see if it makes current leukemia treatments more effective.

Progress from SynthX

SynthX was first launched in April 2024 to turn research from Rice and Houston Methodist into real-world cancer treatments. Within a year, the center had secured $1.5 million in grant money to work on crossing the blood-brain barrier in brain cancer treatments. These latest awards show that SynthX Center continues to bridge the worlds of research and clinical practice.

“This collaboration reflects a shared commitment to team science in cancer research,” Daniela Matei, the director of the Houston Methodist Neal Cancer Center, added in the release. “These are the types of translational and pioneering projects that lead to transformation in patient care.”'

The SynthX Center awarded $90,000 in seed grants to three teams in 2025 and $80,000 to three teams in 2024.

Tesla self-driving mode wasn't to blame in Houston-area crash, report suggests

Tesla news

Federal safety investigators looking into a runaway Tesla that killed a grandmother in her home say the driver had pressed the accelerator to full speed, suggesting the vehicle's self-driving software was not to blame.

The driver had told police that he had the self-driving software turned on, but a report from the National Transportation Safety Board concluded that he had actually overridden that feature when he pushed hard on the pedal. Moments later the Tesla Model 3 raced down a residential street in Katy, Texas, at highway speeds, slammed into a brick home and killed a 76-year-old woman standing in the front room.

The crash last month drew national attention because Tesla CEO Elon Musk is seeking to reassure the public its self-driving feature is safe as he prepares to turn hundreds of thousands of Teslas already on the road into fully automatic vehicles and begin selling two-seated Cybercabs missing steering wheels and pedals.

The crash came two months after officials at a separate federal agency, the National Highway Traffic Safety Administration, announced it was elevating a 2024 investigation of the self-driving feature to new “engineering analysis” level, raising the possibility of a recall of 3.2 million Tesla vehicles.

That NHTSA probe was triggered by crashes where the self-driving feature failed to alert drivers to take control in fog and other poor visibility conditions.

The agency opened an investigation last year into 58 incidents in which Teslas reportedly violated traffic safety laws while using self-driving technology, leading to more than a dozen crashes and fires and nearly two dozen injuries.

Separate from the National Transportation Safety Board, NHTSA is also looking into the Tesla house crash in Texas, one of 46 “special crash” investigations of Tesla's self-driving or driver-assistance technology in the past decade, according to the agency’s records. In more than a dozen of those crashes, at least one person — a driver, passenger or pedestrian — was killed.

Tesla had originally called its driver assistance software Full Self-Driving, or FSD, but auto experts and regulators complained it was misleading because drivers must always keep their eyes on the road and be ready to take over at any time.

The company has since changed the name to Full Self-Driving (Supervised).

Video of the Katy, Texas, accident shows the Tesla traveling at more than 70 mph (112.65 kilometers per hour), jumping a curb then tearing across a lawn before crushing through a brick wall of a home. A woman standing feet away, Martha Avila, was found amid piles of crumbling plaster, split beams and bits of furniture and rushed to a hospital but died.

Sales of Tesla cars still haven't recovered fully from boycotts last year over Musk's political stands, but the stock is rising anyway as he has successfully shifted attention away from the sales figures. He says they matter less now that the company is on the cusp of major technological advances, such as turning Teslas into hands-free vehicles and having its Optimus robots take over for humans for tasks at home and work.

Tesla stock has risen 22% in the past year and is currently trading at 170 times expected annual earnings compared to 20 for the S&P 500.

For its second-quarter financial results, financial analysts surveyed by FactSet expect earnings per share will barely budge — 32 cents versus 33 cents a year earlier — continuing a sixth quarter streak of flat or falling profits.

London AI startup selects Houston for first U.S. office after $20M raise

welcome to houston

London-based AI firm Applied Computing has announced a $20 million Series A round and a new office in Houston.

The new Bayou City office is Applied Computing’s first in the United States and part of its North American expansion. The company is known for its Orbital AI platform, which is tailored for energy operations.

The funding round was led by Houston-based KBR Inc., with participation from San Francisco-based Databricks Ventures. KBR’s investment was first announced in March.

KBR and Applied Computing have also entered into a multi-year agreement to deliver exclusive AI products for the energy sector. KBR already has integrated Orbital into its INSITE 3.0 platform for energy projects, and is also using the product for ammonia production.

Applied Computing’s Orbital platform combines physics-grounded intelligence with models across chemical engineering, time-series forecasting and language, according to the company. The system analyzes sensor readings and can recognize a facility’s equipment constraints and operator activity. The platform can also allow technicians to run simulations of how a change to a facility could affect the rest of its operations.

According to TechCrunch, Applied Computing will use the $20 million to further explore projects and deployments with the energy sector, hire engineering and research positions, and continue to expand internationally, potentially into the Middle East.

The company is also working on deals with a major U.S. stream operator, TechCrunch reports. And Applied Computing shared on LinkedIn that it plans to announce its first partnership with a major European oil company in the coming weeks.

“Yesterday we showed Orbital live in deployments at our demo day at the Energy Institute in London,” Callum Adamson, CEO and co-founder of Applied Computing, posted on LinkedIn on July 16. “Today, we're announcing the capital to scale it globally as well as the launch of our new offices in Houston and Bangalore. In the weeks following, there will be more announcements on our progress, partnerships and deployments.”

The company opened its Bangalore offices in December.

View All Listings